NCT00773240

A Phase III Trial Assessing the Pharmacodynamic Effect and the Tolerability of Grazax Treatment

A Phase III Trial Assessing the Pharmacodynamic Effect and the Tolerability of Grazax Treatment Initiated in the Grass Pollen Season in Subjects With Seasonal Grass Pollen Induced Rhinoconjunctivitis

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 276 (actual)
• Sponsor: ALK-Abelló A/S · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The study assess the pharmacodynamic effect and the tolerability of Grazax treatment initiated in the grass pollen season in subjects with seasonal grass pollen induced rhinoconjunctivitis

Conditions

• Grass Pollen Allergy

Interventions

Type	Name	Description
DRUG	Grazax	1 tablet, 75,000 SQ-T, daily during the trial period
DRUG	placebo	1 placebo tablet, matching the active treatment, daily during the trial period

Timeline

• Start date: 2008-04-01
• Primary completion: 2008-10-01
• Completion: 2009-02-01
• First posted: 2008-10-16
• Last updated: 2011-08-30

Locations

1 site across 1 country: Denmark